-
Product Insights
NewNeuropathy – Drugs In Development, 2024
Empower your strategies with our Neuropathy – Drugs In Development, 2024 report and make more profitable business decisions. Neuropathy, also known as peripheral neuropathy, refers to a condition involving damage or dysfunction of the nerves outside the brain and spinal cord (peripheral nerves). This condition can affect a single nerve or multiple nerves and can result from various causes. Common types include diabetic neuropathy, resulting from diabetes-related nerve damage due to high blood sugar levels; peripheral neuropathy, often due to conditions...
-
Product Insights
NewReflux Esophagitis (Gastroesophageal Reflux Disease) – Drugs In Development, 2024
Empower your strategies with our Reflux Esophagitis (Gastroesophageal Reflux Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Gastroesophageal reflux disease (GERD) refers to a condition where the liquid content of the stomach refluxes into the esophagus. It is a chronic condition. The symptoms of GERD are nausea, heartburn, and vomiting. The predisposing factors include eating large meals, which can cause the lower esophageal sphincter (LES) to open inappropriately, as well as obesity, pregnancy, greasy food, and...
-
Product Insights
NewEndocrine Gland Disorders – Drugs In Development, 2024
Empower your strategies with our Endocrine Gland Disorders – Drugs In Development, 2024 report and make more profitable business decisions. Endocrine gland disorders are medical conditions that affect the function of the endocrine system, which is a network of glands that produce and release hormones that regulate many body processes. Some common endocrine disorders are diabetes, hyperthyroidism, hypothyroidism, Cushing's disease, and polycystic ovary syndrome (PCOS). These disorders can result from various causes, such as tumors, genetic factors, hormonal imbalances, or autoimmune...
-
Product Insights
NewEsophagitis – Drugs In Development, 2024
Empower your strategies with our Esophagitis – Drugs In Development, 2024 report and make more profitable business decisions. Esophagitis is inflammation of the esophagus, often triggered by acid reflux, infections, medications, or allergies. Symptoms include painful swallowing, heartburn, chest pain, and sometimes bleeding. Common types include reflux esophagitis (due to GERD) and infectious esophagitis (caused by viruses, fungi, or bacteria). Diagnosis involves endoscopy and sometimes imaging tests. Treatment focuses on addressing the underlying cause, using acid-suppressing medications, antibiotics, antifungals, or lifestyle...
-
Product Insights
NewAllergic Rhinitis – Drugs In Development, 2024
Empower your strategies with our Allergic Rhinitis – Drugs In Development, 2024 report and make more profitable business decisions. Allergic rhinitis is an allergic reaction that happens when immune system overreacts to substances that is inhaled. An allergen is something that triggers an allergy. When a person with allergic rhinitis breathes in an allergen such as pollen, mold, animal dander, or dust, the body releases chemicals that cause allergy symptoms. Symptoms of allergic rhinitis include stuffy or runny nose, sneezing, swollen...
-
Product Insights
NewEsophageal Diseases – Drugs In Development, 2024
Empower your strategies with our Esophageal Diseases – Drugs In Development, 2024 report and make more profitable business decisions. Esophageal Diseases, which are characterized by weakened muscles and narrowing of the esophageal opening, often lead to difficulties in digestion and swallowing. The esophagus is the tube-shaped muscle that connects the throat to the stomach. Esophageal diseases occur when the esophagus muscle and opening become weak. The most common problem with the esophagus is GERD (gastroesophageal reflux disease). With GERD, a muscle...
-
Product Insights
New3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase – Drugs In Development, 2024
The 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase pipeline drugs market research report outlays comprehensive information on the 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Metabolic Disorders, Cardiovascular, Infectious Disease, and Respiratory which include indications of Dyslipidemia, Hypercholesterolemia, Hypertension, Idiopathic (Essential) Hypertension, Bacterial Infections, Sepsis, Asthma, and Acute Respiratory...
-
Product Insights
NewRhinitis – Drugs In Development, 2024
Empower your strategies with our Rhinitis – Drugs In Development, 2024 report and make more profitable business decisions. Rhinitis is inflammation and swelling of the mucous membrane of the nose, characterized by a runny nose and stuffiness and usually caused by the common cold or a seasonal allergy. Rhinitis is classified as allergic or nonallergic. The cause of nonallergic rhinitis is usually a viral infection, although irritants can cause it. The nose is the most commonly infected part of the upper...